Information letter on Airbufo Forspiro 160 µg/4,5 mg and 320 µg/9 mg: possible failure of dose delivery from the first use
2024.11.22
Active substance: Budesonide and Formoterole
The company Sandoz GmbH informs about a possible failure of dose delivery in several batches of Airbufo Forspiro. According to the company, the mechanical defect can be recognized from the first use, as the blister strip remains immobile. The company asks pharmacists to advise patients to check the function of the inhaler before use or to do so themselves.
Further information can also be found on the website of Arzneimittelkommission der Deutschen Apotheker (AMK).